Celldex Therapeutics to present poster on its first antibody-drug conjugate product

Download PDF Copy

Dec 8 2009

Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that the Company’s first antibody-drug conjugate (ADC) product candidate, CDX-011 (formerly CR011-vcMMAE), for the treatment of locally advanced or metastatic breast cancer will be the subject of a poster presentation at the 2009 San Antonio Breast Cancer Symposium.

Poster #6096, “A Phase I/II Study of CR011-VcMMAE, an Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Breast Cancer,” will include safety, tolerability and efficacy data. It is scheduled for presentation during Poster Session 6 in Exhibit Halls A-B from 7:00 a.m. to 9:00 a.m. CST on Sunday, December 13, 2009 at the Henry B. Gonzalez Convention Center in San Antonio, TX.

http://www.celldextherapeutics.com

Posted in: Women's Health News | Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

Penn State researchers reveal new function of antibody-producing cells

Innovative bispecific antibody targets LAG-3 to treat autoimmune diseases

New antibody delivery system boosts Alzheimer's treatment in mice

New microchip tracks antibody-virus interactions from a single drop of blood

Single antibody causes a rare but dangerous reaction to widely-used blood thinner

Dengue antibody may block the spread of Zika virus in vulnerable areas of the body

Nasal antibody spray shields mice from pollen-triggered allergies and asthma

Breakthrough technology enables faster and cheaper antibody analysis

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.